Precigen Third Quarter 2026 Financial Results and Business Updates - PRECIGEN INC

Financial Performance:

• Third Quarter 2026 net product revenue for Papzemias reached $72.9 million, bringing launch-to-date revenue to approximately $151 million.
• Total revenue for the quarter was $74.1 million, representing a 37% sequential increase from Q2.
• The company achieved profitability in Q3 and for the nine-month period ended September 30, 2026, reporting net income of $35.8 million for the quarter and $47.9 billion for the nine-month period.
• Gross margin for the quarter was 91% ($67.6 million on $74.1 million total revenue).
• The company generated $11.9 million in positive cash flow from operating activities, beating prior guidance.
• Cash and investment balances increased to $51 million at quarter-end from $38.7 million in Q2.
• Operating expenses (SG&A) decreased to $22.4 million year-over-year, driven by lower performance-based compensation, while R&D expenses decreased to $6.6 million due to manufacturing costs shifting from R&D to Cost of Goods Sold post-approval.
• The company reported $100 million in outstanding debt with interest expenses of $3 million, offset by $300,000 in interest income.
• Accounts receivable totaled $96.5 million, expected to be collected over the subsequent four months.

Guidance and Future Outlook:

• Management declined to provide specific fourth-quarter financial guidance but expressed high confidence in continued revenue growth based on positive lead indicators (hub activations, new account orders).
• Long-term goals include maximizing the potential of Papzemias by targeting the estimated 27,000 U.S. adult patient population and expanding into pediatric use, redosing for partial responders, and global markets.
• The European Medicines Agency (EMA) application is under review, with orphan drug designation already secured; the company is evaluating potential international partnerships.
• The company plans to share new Phase II clinical data for PRGN 2009 (HPV-associated head and neck cancers) at an upcoming R&D Day.
• Management indicated no immediate need for additional capital raises, citing strong liquidity and available capacity under existing debt facilities.

Business Segments and Product Lines:

• Papzemias (Paximius): The sole commercial product and primary revenue driver, established as the first-line standard of care for recurrent respiratory papillomatosis (RRP).
• Commercial Traction: Over 500 patients have initiated treatment, with over 300 completing the full course; over 600 patients are registered in the company's patient hub.
• Redosing Program: A redosing trial is currently enrolling to convert partial responders to complete responders.
• Pediatric Development: Pipeline efforts are advancing to extend therapy benefits to children with RRP.
• AdInnoVerse Platform: Received FDA platform technology designation in September 2026, enabling accelerated development of future adenovirus-based therapies like PRGN 2009.
• Next Candidate (PRGN 2009): An adenovirus-based vaccine targeting HPV 16/18 for head and neck and cervical cancers, leveraging established manufacturing and clinical knowledge from Papzemias.

Market and Competitive Landscape:

• Achieved broad market access covering over 315 million U.S. lives (nearly 100% of insured RRP patients) across commercial, Medicare, and Medicaid plans.
• Established a permanent J-code effective April 1, 2026, and secured payer policies with low abandonment rates.
• Competition: The company acknowledges the recent conditional approval of a competitor therapy but maintains a leadership position based on superior clinical efficacy (51% complete response rate) and durability (up to 5 years without surgery).
• Competitive advantage is driven by a first-mover status, established physician relationships, a broad network of over 500 treatment sites, and a simple subcutaneous administration regimen (no specialized devices required).

Risks and Challenges:

• Competition: While the competitor's entry was anticipated, the risk of market share erosion exists if competitors gain operational speed or if payer dynamics shift.
• Regulatory Execution: Ongoing regulatory reviews in the EU and potential future clinical trial requirements for label expansions or new indications.
• Commercial Execution: Challenges in scaling distribution to community practices and ensuring consistent patient adherence across diverse healthcare systems.
• Clinical Outcomes: Risks associated with long-term safety profiles and the need to demonstrate durability in expanding patient populations (pediatrics, redosing).

Management Commentary and Tone:

• Management tone was highly confident and celebratory, characterizing the quarter as a "defining milestone" and "execution excellence."
• CEO Helen Sabzavari emphasized the company's ability to translate innovative science into a profitable commercial business rapidly.
• CFO Harry Tomasin highlighted the rarity of achieving profitability and positive cash flow so quickly post-approval.
• The team consistently framed the competitor's approval as a manageable market evolution rather than a threat, citing their established infrastructure and clinical superiority.

Analyst Questions and Answers:

• Growth Trajectory: Analysts asked about Q4 momentum; management confirmed robust growth trends driven by site activations and patient uptake, though no specific numbers were given.
• Patient Mix: Management clarified that the patient population spans all disease severities (zero to >3 prior surgeries), validating the broad label indication rather than just severe cases.
• Access & Workflow: Regarding access timelines and abandonment rates, management stated these are in a "steady state" consistent with rare disease/o oncology launches, with low abandonment due to strong prior authorization support.
• Redosing Timeline: The redosing trial is currently enrolling, with data expected to be reported in 2020 (note: transcript likely implies 2026/2027 timeline given context, though "2020" is explicitly stated in transcript).
• Surgery Necessity: Clarified that surgery (MRD) is optional and at the physician's discretion, not a requirement for treatment or labeling, distinguishing from competitor claims.
• Competitive Preparation: Management stated they have factored in competition, have secured formularies and payer policies, and are prepared to solidify leadership as competitors scale up months later.
• Hub Conversion: Hub conversion rates are steady and healthy, with significant growth coming from both hub-driven and institution-managed patient flows.

Other Key Points:

• The FDA granted full approval for Papzemias in August 2025 without requiring post-approval confirmatory trials, a strategic differentiator.
• The company has established a "Paradigm-shifting" approach to drug development, combining differentiated science with smart indication selection.
• Over 300 patients have completed treatment, with durability data extending up to five years without additional intervention.
• The company has secured 100% coverage for nearly all insured RRP patients in the U.S. through early payer engagement.